Biofilm inhibition of Inula viscosa (L.) Aiton and Globularia alypum L. extracts against Candida infectious pathogens and In vivo action on galleria mellonella model

The increasing importance of fungal infections has fueled the search for new beneficial alternatives substance from plant extracts. The current study investigates the antifungal and antibiofilm activity of Inula viscosa (L.) Aiton and Globularia alypum (L.) leaves extracts against Candida both in vitro and in vivo. The inhibition of planktonic and sessile Candida albicans and Candida glabrata growth using both leaf extracts are evaluated. Moreover; an in vivo infection model using Galleria mellonella larvae; infected and treated with the extracts are performed. All extracts show fungicidal activity; with a minimum fungicidal concentration (MFC) ranging from 128 to 512 mu g mL(-1) against the two selected strains of Candida. In particular, the best results are obtained with methanolic extract ofI. viscosa and G. alypum with an MFC value of 128 mu g mL(-1). The extracts are capable to prevent 90% of biofilm development at minor concentrations ranging from 100.71 +/- 2.49 mu g mL(-1) to 380.4 +/- 0.92 mu g mL(-1). In vivo, tests on Galleria mellonella larvae show that the extracts increase the survival of the larvae infected with Candida. The attained results reveal that I. viscosa and G. alypum extracts may be considered as new antifungal agents and biofilm inhibiting agents for the pharmaceutical and agro-food field

Filière agro-alimentaire.

Monographie sectorielle pour l'Agence de Développement et d'Urbanisme de Lille Métropole (décembre

Comparative reviews of diagnostic test accuracy in imaging research: evaluation of current practices.

PURPOSE The purpose of this methodological review was to determine the extent to which comparative imaging systematic reviews of diagnostic test accuracy (DTA) use primary studies with comparative or non-comparative designs. METHODS MEDLINE was used to identify DTA systematic reviews published in imaging journals between January 2000 and May 2018. INCLUSION CRITERIA systematic reviews comparing at least two index tests (one of which was imaging-based); review characteristics were extracted. Study design and other characteristics of primary studies included in the systematic reviews were evaluated. RESULTS One hundred three comparative imaging reviews were included; 11 (11%) included only comparative studies, 12 (11%) included only non-comparative primary studies, and 80 (78%) included both comparative and non-comparative primary studies. For reviews containing both comparative and non-comparative primary studies, the median proportion of non-comparative primary studies was 81% (IQR 57-90%). Of 92 reviews that included non-comparative primary studies, 86% did not recognize this as a limitation. Furthermore, among 4182 primary studies, 3438 (82%) were non-comparative and 744 (18%) were comparative in design. CONCLUSION Most primary studies included in comparative imaging reviews are non-comparative in design and awareness of the risk of bias associated with this is low. This may lead to incorrect conclusions about the relative accuracy of diagnostic tests and be counter-productive for informing guidelines and funding decisions about imaging tests. KEY POINTS • Few comparative accuracy imaging reviews include only primary studies with optimal comparative study designs. Among the rest, few recognize the risk of bias conferred from inclusion of primary studies with non-comparative designs. • The demand for accurate comparative accuracy data combined with minimal awareness of valid comparative study designs may lead to counter-productive research and inadequately supported clinical decisions for diagnostic tests. • Using comparative accuracy imaging reviews with a high risk of bias to inform guidelines and funding decisions may have detrimental impacts on patient care